Janssen debuts schizophrenia awareness doc

Share this article:
Janssen debuts schizophrenia awareness doc
Janssen debuts schizophrenia awareness doc
Johnson & Johnson is back in the film game with Janssen's half-hour documentary Living with Schizophrenia: A Call for Hope and Recovery.

The unbranded film, which follows several young people with schizophrenia and their families, aims to lessen the fear and stigma associated with the condition. It debuted Friday in Washington, DC, and will be distributed through a series of community-based events, via advocacy groups and online at hopeandrecoveryfilm.com.

The film, said director Emily Abt, “highlights the stories that don't make the headlines – the stories of hope and promise.” Abt's grandmother struggled with schizophrenia.

Janssen's Risperdal and Invega franchises are indicated for the treatment of schizophrenia, and the company sponsored an earlier documentary on the topic. In 2007, J&J's Centocor unit sponsored “Innerstate” an hour-long documentary following a similar formula, following several young people struggling with autoimmune disorders. Centocor makes Remicade for rheumatoid arthritis, psoriasis and Crohn's Disease.
Share this article:

Email Newsletters

More in News

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.

GSK second-quarter sales disappoint

GSK second-quarter sales disappoint

Executives urge analysts to focus on the company's long-term potential.

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union